Management Team

Executive Officers

Thomas W. Burns , , , President, Chief Executive Officer

Mr. Burns has served as our President, Chief Executive Officer and as a member of our Board of Directors since March 2002. Mr. Burns has also been a member of the board of directors of DOSE Medical Corporation since October 2009 and served as its chief executive officer and president from March 2010 until June 2015. Mr. Burns has a proven record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices, ophthalmic pharmaceuticals, drug delivery technologies, surgical products and over-the-counter products. Prior to joining our company, Mr. Burns led Eyetech Pharmaceuticals, Inc. (acquired by OSI Pharmaceuticals, Inc.) as its president and chief operating officer, and as a director. From 1990 to 1997, Mr. Burns served as senior vice president and general manager of Chiron Vision Corporation (acquired by Bausch & Lomb, Inc.), and then as vice president, global strategy and general manager, refractive surgery, of Bausch & Lomb from 1998 to 2000. Mr. Burns has also served as an entrepreneur in residence at Versant Ventures Management, LLC, an entity affiliated with one of our principal stockholders. Mr. Burns received a B.A. from Yale University.

Chris M. Calcaterra , , , Chief Operating Officer

Mr. Calcaterra has served as our chief operating officer since February 2017. He was previously our chief commercial officer, a position he had held since joining Glaukos in April 2008. Mr. Calcaterra has more than 25 years of experience in the ophthalmic medical technology industry. Prior to joining our Company, Mr. Calcaterra was senior vice president at Advanced Medical Optics, Inc. (acquired by Abbott Laboratories), and was responsible for its cataract business. Prior to that position, Mr. Calcaterra held increasingly responsible vice president positions in a variety of sales and marketing roles at Advanced Medical Optics, Inc., as well as its predecessor surgical division business at Allergan, Inc. Mr. Calcaterra has a B.S. from Miami University and an M.B.A. from Xavier University, and he was previously a board member of WaveTec Vision Systems, Inc. (acquired by Novartis)

Joseph E. Gilliam , , , Chief Financial Officer, Senior Vice President, Corporate Development

Mr. Gilliam has served as our chief financial officer and senior vice president, corporate development since May 2017. He has nearly 20 years of experience across capital markets, strategic advisory, finance and banking services with an emphasis on the life sciences industry, including the medical technology, diagnostics and biotechnology sectors. From 2013 to May 2017, he was a managing director in the healthcare investment banking group at JPMorgan, where he led the Glaukos initial public offering for the firm. From 2001 to 2013, Mr. Gilliam held increasingly responsible positions at JPMorgan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bond offerings and other transactions. His prior experience includes positions at The Beacon Group (which was combined with JPMorgan and Chase Manhattan in 2001) and PricewaterhouseCoopers. Mr. Gilliam has a B.S. in accounting from the Kelly School of Business at Indiana University.

Key Employees

Robert L. Davis , , , Senior Vice President, General Counsel and Quality Affairs

Robert L. Davis has served as our senior vice president and general counsel since June 2015. From April 2008 to May 2015, Mr. Davis served as senior vice president, general counsel and secretary for Targus Group International, Inc., a global designer, manufacturer and distributor of cases and accessories for mobile electronic devices. From December 1999 to April 2008, Mr. Davis served in various executive positions, including senior vice president, corporate development and assistant general counsel, with Meade Instruments Corp., a publicly traded designer, manufacturer and distributor of precision optical products. From September 1994 to December 1999, Mr. Davis was in private legal practice with the law firms of O’Melveny & Myers, LLP and Morrison & Foerster, LLP. Mr. Davis is an active member of the California State Bar, admitted in 1994, and holds both a B.A. and a J.D. from Brigham Young University.

Michele M. Allegretto , , , Vice President, Human Resources

Michele M. Allegretto has served as our vice president, human resources since May 2015. From October 2005 to May 2015, Ms. Allegretto served as director global business human resources with Abbott Medical Optics, a global ophthalmic medical device division of Abbott Laboratories. From January 2002 to October 2005, Ms. Allegretto was director of human resources for The Wet Seal, Inc., a publicly traded national women’s retail chain. From April 1995 to December 2001, Ms. Allegretto served in several different leadership positions across three divisions of The Walt Disney Company, including the director recruitment for Walt Disney Studios. Ms. Allegretto holds a B.A. from San Diego State University and a master’s degree from California State University, Long Beach.

David S. Haffner , , , Senior Vice President, New Technologies

David S. Haffner has served as our senior vice president, new technologies since February 2017. He was previously our vice president, product development, a position he had held since joining Glaukos in February 2001. Immediately prior to joining our company, Mr. Haffner consulted to the medical industry in the areas of medical device and pharmaceutical product development, with emphasis on mechanical systems for pharmaceutical drug delivery. Prior to this, he spent over 10 years at Allergan, Inc. leading teams and departments in several divisions, including surgical products, pharmaceuticals, and worldwide operations. Mr. Haffner has directed several multi-million dollar programs in both research and development and operations involving development and commercialization of ophthalmic products and technologies targeted at cataract, glaucoma, dry eye and nasal disease groups. The scope of his work has spanned a broad diversity of technical disciplines including operations management, process development, site construction, validation, injection molding, automated assembly, packaging, product design, engineering analysis, and industrial design. Mr. Haffner holds a B.S. from California State University, Long Beach

Harold A. Heitzmann , , Ph.D. , , Senior Vice President, Applied Research & Engineering

Harold A. Heitzmann has served as our senior vice president, applied research and engineering since February 2017. He was previously our vice president, applied research, a position he had held since joining Glaukos in January 2007. He has over 30 years' experience in development of medical devices at five startup companies and at Edwards Lifesciences Corporation, including three previous positions as vice president. Dr. Heitzmann has led development of commercial products for blood gas monitoring, angioplasty, intracranial pressure monitoring, electrophysiology, coronary stenting, thrombectomy, venous oxygen saturation monitoring, and antimicrobial catheterization. He holds 18 issued U.S. patents and has taught at University of California, Irvine Extension in the Clinical Trials and Medical Product Development certificate programs. Dr. Heitzmann holds a B.A. from Cornell University and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University, where he co-invented avidin-biotin staining for microscopy.

L. Jay Katz , , MD, FACS , , Chief Medical Officer

Dr. Katz has served as our Chief Medical Officer since February 2017. He is currently employed by our company on a part-time basis while maintaining his Philadelphia-based ophthalmology practice and involvement in clinical research and medical education. Dr. Katz completed his glaucoma fellowship at Wills Eye Hospital in Philadelphia in 1985 and has been affiliated with the hospital since that time, currently serving as its director of glaucoma service. Since 1997, he has also served as a professor of ophthalmology at Jefferson Medical College at Thomas Jefferson University. He is a former member of the board and past treasurer of the American Glaucoma Society, a diplomate and associate examiner for the American Board of Ophthalmology and a fellow, member-at-large and past president of the Philadelphia Metro chapter of the American College of Surgeons. He has published more than 200 articles in ophthalmic journals and served as an investigator in landmark glaucoma trials, including the Advanced Glaucoma Intervention Study (AGIS) and Collaborative Initial Glaucoma Treatment Study (CIGTS). Dr. Katz completed his residency at Yale University and internship at the University of Virginia after earning his M.D. from Yale University Medical School. He holds a B.A. (summa cum laude) from Case Western Reserve University.

Nicholas Tarantino , , O.D., F.A.A.O. , , Senior Vice President, Global Clinical and Medical Affairs

Nicholas Tarantino has served as our senior vice president, global clinical and medical affairs since March 2018. From 2013 to March 2018, he was the chief clinical and regulatory officer and head of R&D for AcuFocus, Inc. From 2012 to 2013, he was vice president, global clinical research and regulatory affairs for Hoya Surgical Optics. From 2009 to 2012, Dr. Tarantino was the global head of clinical research and development for Abbott Medical Optics, Inc., following the 2009 acquisition by Abbott Laboratories of Advanced Medical Optics, Inc. (AMO). From 2002 to 2009, he held several senior-level positions at AMO, including vice president, global clinical research and development. From 1983 to 2002, he held a series of positions with increasing responsibility at Allergan, Inc. In addition, from 2010 to 2013, Dr. Tarantino was the primary industry representative to the Panel of the Medical Devices Advisory Committee in the Food & Drug Administration’s (FDA) Center for Devices and Radiological Health. He holds an O.D. from the Southern California College of Optometry and a B.S. from San Diego State University.

Jane E. Rady , , , Senior Vice President, Corporate Strategy and Business Development

Jane E. Rady has served as our senior vice president, corporate strategy and business development since April 2018. From 2017 to April 2018, she was vice president, business development for Johnson & Johnson Surgical Vision, following the 2017 acquisition by Johnson & Johnson of Abbott Medical Optics, a division of Abbott Laboratories. From 2009 to 2017, she was divisional vice president, business development for Abbott Medical Optics. From 2002 to 2009, she held several executive leadership positions at Advanced Medical Optics, Inc. (AMO), which was acquired by Abbott Laboratories in 2009. While at AMO, Ms. Rady headed various functions, including business development, strategic planning, research and development, clinical development, regulatory affairs and government affairs. Her prior experiences includes positions at Monsanto Corporation, G.D. Searle and Abbott Laboratories. Ms. Rady holds a B.S. in biology and a M.S. in molecular biology/microbiology from the University of Illinois and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.

Judy F. Gordon , , D.V.M. , , Senior Vice President, Regulatory Affairs

Dr. Gordon has served as our senior vice president of regulatory affairs since April 2018. She is the founder and senior consultant at ClinReg Consulting Services, Inc., a preeminent regulatory consulting firm that advises pharmaceutical and medical device companies on a range of matters, including clinical protocol development, interactions with a submission to the U.S. Food and Drug Administration (FDA) and development of worldwide regulatory strategies. Dr. Gordon has conducted clinical trials of recombinant and plasma-derived biologic drugs, novel and 505(b)2 pharmaceuticals and Class I, II and III medical devices. She has been involved in multiple successful presentations to FDA and more than 200 regulatory approvals. From 1986 to 1998, she held a series of increasingly responsible positions at Chiron Vision, which was acquired in 1998 by Bausch & Lomb. Dr. Gordon is employed by our company on a part-time basis while continuing in her regulatory practice. Dr. Gordon earned an undergraduate degree from the University of California Los Angeles and a D.V.M. from the University of Bologna, Italy.

Contact Investor Relations

Glaukos Corporation
229 Avenida Fabricante
San Clemente, CA 92672

Telephone: 949-481-0510
Fax: 949-367-9984
Email: investors@glaukos.com